Al Gianchetti, XyloCor Therapeutics CEO
XyloCor raises $67.5M Series B, updates pivotal gene therapy trial plans
XyloCor Therapeutics has closed a $67.5 million Series B round to fund mid-stage development of its cardiac gene therapy.
Two years ago, the biotech said …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
